Ubrogepant (Ubrelvy™) is an orally administered, small molecule, 
highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was 
developed by Allergan under license to Merck & Co. as an acute treatment for 
migraine. In December 2019, ubrogepant received its first global approval in the 
USA for the acute treatment of migraine (± aura) in adults. This article 
summarizes the milestones in the development of ubrogepant leading to its first 
global approval for the acute treatment of migraine (± aura) in adults.